Search Results 141-150 of 224 for ⚠입플보증 【룰라보증.com / 가입코드 9000】 메이저사이트⚠

  1. Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer - Mayo Clinic

    Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor ...

  2. Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  3. Study of TJ011133 in Participants With Relapsed/ Refractory Advanced Solid Tumors and Lymphoma - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  4. Clinical trials - Urology

    Urology — Learn about innovative diagnosis and treatment options for urologic diseases, including cancers, at Mayo Clinic.

  5. A Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy in Patients with Gastric or Gastroesophageal Cancer - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

  6. ... SITE,293 260000014,HC APPLICATION OF ON BODY INJECTOR,129 260000016,HC INTRO NDL/CATH VEIN,548 260000017,HC COLLECT BLOOD FROM IMPLANT VAD,196 260000018,HC ...

  7. Insurance approvals: pre-certification and prior authorizations - Mayo Clinic

    ... site at which you will receive services. Please contact your insurance carrier directly to ask about the status of any pre-certification. Home · Billing and ...

  8. LUPKYNIS US Registry Trial - Mayo Clinic

    This observational study is a registry designed to assess the utilization and effectiveness of LUPKYNIS in adult patients with lupus nephritis (LN) in the ...

  9. Clinical trials - Oncology (Medical)

    This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...

  10. Single-Ascending Dose Study of JK07 in Subjects With HFpEF - Mayo Clinic

    The purpose of this study is to assess the safety and tolerability profile of JK07, administered intravenously, according to protocol-defined dosing regimen.